{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T16:33:59Z","timestamp":1778344439502,"version":"3.51.4"},"reference-count":70,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2022,5,28]],"date-time":"2022-05-28T00:00:00Z","timestamp":1653696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Italian Ministry of Health\u2014Ricerca Corrente."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Introduction: Mediastinal or hilar lymph node metastases are a challenging condition in patients affected by solid tumors. Stereotactic body radiation therapy (SBRT) could play a crucial role in the therapeutic management and in the so-called \u201cno-fly zone\u201d, delivering high doses of radiation in relatively few treatment fractions with excellent sparing of healthy surrounding tissues and low toxicity. The aim of this systematic review is to evaluate the feasibility and tolerability of SBRT in the treatment of mediastinal and hilar lesions with particular regard to the radiotherapy doses, dose constraints for organs at risk, and clinical outcomes. Materials and methods: Two blinded investigators performed a critical review of the Medline, Web of Knowledge, Google Scholar, Scopus, and Cochrane databases according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement (PRISMA), starting from a specific question: What is the clinical impact of SBRT for the treatment of oligorecurrent\/oligoprogressive mediastinal and hilar metastasis? All retrospective and prospective clinical trials published in English up to February 2022 were analyzed. Results: A total of 552 articles were identified and 12 of them were selected with a total number of 478 patients treated with SBRT for mediastinal or hilar node recurrence. All the studies are retrospective, published between 2015 and 2021 with a median follow-up ranging from 12 to 42.2 months. Studies following SBRT for lung lesions or retreatments after thorax radiotherapy for stage III lung cancer were also included. The studies showed extensive heterogeneity in terms of patient and treatment characteristics. Non-small cell lung cancer was the most frequently reported histology. Different dose schemes were used, with a higher prevalence of 4\u20138 Gy in 5 or 6 fractions, but dose escalation was also used up to 52 Gy in 4 fractions with dose constraints mainly derived from RTOG 0813 trial. The radiotherapy technique most frequently used was volumetric modulated arc therapy (VMAT) with a median PTV volume ranging from 7 to 25.7 cc. The clinical outcome seems to be very encouraging with 1-year local control (LC), overall survival (OS) and progression-free survival (PFS) rates ranging from 84 to 94%, 53 to 88% and 23 to 53.9%, respectively. Half of the studies did not report toxicity greater than G3 and only five cases of fatal toxicity were reported. CONCLUSIONS: From the present review, it is not possible to draw definitive conclusions because of the heterogeneity of the studies analyzed. However, SBRT appears to be a safe and effective option in the treatment of mediastinal and hilar lymph node recurrence, with a good toxicity profile. Its use in clinical practice is still limited, and there is extensive heterogeneity in patient selection and fractionation schedules. Good performance status, small PTV volume, absence of previous thoracic irradiation, and administration of a high biologically effective dose (BED) seem to be factors that correlate with greater local control and better survival rates. In the presence of symptoms related to the thoracic lymph nodes, SBRT determines a rapid control that lasts over time. We look forward to the prospective studies that are underway for definitive conclusions.<\/jats:p>","DOI":"10.3390\/cancers14112680","type":"journal-article","created":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T08:50:51Z","timestamp":1653814251000},"page":"2680","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Stereotactic Body Radiation Therapy (SBRT) for Oligorecurrent\/Oligoprogressive Mediastinal and Hilar Lymph Node Metastasis: A Systematic Review"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8890-3460","authenticated-orcid":false,"given":"Salvatore","family":"Cozzi","sequence":"first","affiliation":[{"name":"Radiation Therapy Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuele","family":"Al\u00ec","sequence":"additional","affiliation":[{"name":"Radiation Therapy Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lilia","family":"Bardoscia","sequence":"additional","affiliation":[{"name":"Radiation Oncology Unit, S. Luca Hospital, Healthcare Company Tuscany Nord Ovest, 55100 Lucca, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masoumeh","family":"Najafi","sequence":"additional","affiliation":[{"name":"Skull Base Research Center, Iran University of Medical Sciences, Tehran 1997667665, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Botti","sequence":"additional","affiliation":[{"name":"Medical Physics Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gladys","family":"Blandino","sequence":"additional","affiliation":[{"name":"Radiation Therapy Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia","family":"Giaccherini","sequence":"additional","affiliation":[{"name":"Radiation Therapy Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Paola","family":"Ruggieri","sequence":"additional","affiliation":[{"name":"Radiation Therapy Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Augugliaro","sequence":"additional","affiliation":[{"name":"Radiation Therapy Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9482-1832","authenticated-orcid":false,"given":"Federico","family":"Iori","sequence":"additional","affiliation":[{"name":"Radiation Therapy Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Sardaro","sequence":"additional","affiliation":[{"name":"Interdisciplinary Department of Medicine, Section of Radiology and Radiation Oncology, University of Bari \u201cAldo Moro\u201d, 70124 Bari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9686-7298","authenticated-orcid":false,"given":"Cinzia","family":"Iotti","sequence":"additional","affiliation":[{"name":"Radiation Therapy Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrizia","family":"Ciammella","sequence":"additional","affiliation":[{"name":"Radiation Therapy Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,5,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1023\/B:JORA.0000010880.40483.c4","article-title":"Radiosurgery for Tumors in the Body: Clinical Experience Using a New Method","volume":"1","author":"Blomgren","year":"1998","journal-title":"J. Radiosurgery"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s10147-006-0646-6","article-title":"Current status of stereotactic body radiotherapy for lung cancer","volume":"12","author":"Nagata","year":"2007","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_3","first-page":"1419","article-title":"Stereotactic body radiation therapy. Rationale, techniques, applications, and optimization","volume":"18","author":"Song","year":"2004","journal-title":"Oncology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5603\/RPOR.a2021.0129","article-title":"Special stereotactic radiotherapy techniques: Procedures and equipment for treatment simulation and dose delivery","volume":"27","author":"Paoletti","year":"2022","journal-title":"Rep. Pract. Oncol. Radiother."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.ijrobp.2005.03.073","article-title":"Stereotactic body radiation therapy of early-stage non-small-cell lung carcinoma: Phase I study","volume":"63","author":"McGarry","year":"2005","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"4833","DOI":"10.1200\/JCO.2006.07.5937","article-title":"Excessive Toxicity When Treating Central Tumors in a Phase II Study of Stereotactic Body Radiation Therapy for Medically Inoperable Early-Stage Lung Cancer","volume":"24","author":"Timmerman","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/S1470-2045(15)70168-3","article-title":"Stereotactic ablative radiotherapy versus lobectomy for operable stage I nonsmall-cell lung cancer: A pooled analysis of two randomised trials","volume":"1","author":"Chang","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.21037\/jtd.2016.08.59","article-title":"SBRT versus lobectomy in stage I NSCLC: Knowns, unknowns and its interpretation","volume":"8","author":"Guckenberger","year":"2016","journal-title":"J. Thorac. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1007\/s00345-014-1427-x","article-title":"Stereotactic radiotherapy for isolated nodal recurrence of prostate cancer","volume":"33","author":"Detti","year":"2015","journal-title":"World J. Urol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.ijrobp.2010.05.032","article-title":"Clinical outcome of hypofractionated stereotactic radiotherapy for abdominal lymph node metastases","volume":"81","author":"Bignardi","year":"2011","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/COC.0b013e3182610878","article-title":"Linac-based stereotactic body radiotherapy for oligometastatic patients with single abdominal lymph node recurrent cancer","volume":"37","author":"Piperno","year":"2014","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/1748-717X-7-204","article-title":"Volumetric modulated arc therapy with flattening filter free beams for isolated abdominal\/pelvic lymph nodes: Report of dosimetric and early clinical results in oligometastatic patients","volume":"7","author":"Alongi","year":"2012","journal-title":"Radiat. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Cozzi, S., Botti, A., Timon, G., Blandino, G., Najafi, M., Manicone, M., Bardoscia, L., Ruggieri, M.P., Ciammella, P., and Iotti, C. (2021). Prognostic factors, efficacy, and toxicity of involved-node stereotactic body radiation therapy for lymph node oligorecurrent prostate cancer: An investigation of 117 pelvic lymph nodes. Strahlenther. Onkol.","DOI":"10.1007\/s00066-021-01871-5"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e115","DOI":"10.1016\/j.clon.2016.04.040","article-title":"Pattern of progression after stereotactic body radiotherapy for oligometastatic prostate cancer nodal recurrences","volume":"28","author":"Ost","year":"2016","journal-title":"Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","article-title":"Oligometastases","volume":"13","author":"Hellman","year":"1995","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1097\/PPO.0000000000000143","article-title":"Radiation therapy for oligometastatic non-small cell lung cancer: Theory and practice","volume":"21","author":"Rusthoven","year":"2015","journal-title":"Cancer J."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"102894","DOI":"10.1016\/j.critrevonc.2020.102894","article-title":"The use of radiation therapy for oligoprogressive\/oligopersistent oncogene-driven non small cell lung cancer: State of the art","volume":"148","author":"Franceschini","year":"2020","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0167-8140(01)00478-9","article-title":"Adjuvant radiotherapy in non-small cell lung cancer with pathological stage I: Definitive results of a phase III randomized trial","volume":"62","author":"Trodella","year":"2002","journal-title":"Radiother. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.ijrobp.2016.03.050","article-title":"Radiosensitivity differences between liver metastases based on primary histology suggest implications for clinical outcomes after stereotactic body radiation therapy","volume":"95","author":"Ahmed","year":"2016","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., and Altman, D. (2009). Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med., 6.","DOI":"10.2427\/5768"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"20181026","DOI":"10.1259\/bjr.20181026","article-title":"Can thoracic nodes oligometastases be safely treated with image guided hypofractionated radiation therapy?BR","volume":"92","author":"Franceschini","year":"2019","journal-title":"J. Radiol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"642","DOI":"10.21037\/jtd-20-2659","article-title":"A single institutional experience with central lung stereotactic body radiation therapy demonstrating encouraging results with increased inter-fraction time","volume":"13","author":"Kowalchuk","year":"2021","journal-title":"J. Thorac. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"15690","DOI":"10.18632\/oncotarget.3704","article-title":"Clinical evaluation of stereotactic radiation therapy for recurrent or second primary mediastinal lymph node metastases originating from non-small cell lung cancer","volume":"6","author":"Meng","year":"2015","journal-title":"Oncotarget"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"53321","DOI":"10.18632\/oncotarget.10826","article-title":"Volumetric modulated arc therapy for thoracic node metastases: A safe and effective treatment for a neglected disease","volume":"7","author":"Franceschini","year":"2016","journal-title":"Oncotarget"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"18135","DOI":"10.18632\/oncotarget.7636","article-title":"Stereotactic radiation therapy for oligometastases or oligorecurrence within mediastinal lymph nodes","volume":"7","author":"Wang","year":"2016","journal-title":"Oncotarget"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.ijrobp.2020.10.004","article-title":"Stereotactic Body Radiation Therapy for Mediastinal and Hilar Lymph Node Metastases","volume":"109","author":"Shahi","year":"2021","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/j.jtho.2016.05.003","article-title":"Isolated Nodal Failure after Stereotactic Body Radiotherapy for Lung Cancer: The Role for Salvage Mediastinal Radiotherapy","volume":"11","author":"Ward","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13014-017-0820-1","article-title":"Institutional analysis of stereotactic body radiotherapy (SBRT) for oligometastatic lymph node metastases","volume":"12","author":"Yeung","year":"2017","journal-title":"Radiat. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s11604-018-0776-6","article-title":"Definitive radiotherapy for hilar and\/or mediastinal lymph node metastases after stereotactic body radiotherapy or surgery for stage I non-small cell lung cancer: 5-year results","volume":"36","author":"Manabe","year":"2018","journal-title":"Jpn. J. Radiol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lungcan.2017.10.014","article-title":"Stereotactic body radiation therapy for isolated hilar and mediastinal non-small cell lung cancers","volume":"115","author":"Horne","year":"2018","journal-title":"Lung Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1080\/0284186X.2018.1486040","article-title":"Stereotactic body radiation therapy for mediastinal lymph node metastases: How do we fly in a \u2018no-fly zone\u2019?","volume":"57","author":"Muto","year":"2018","journal-title":"Acta Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1111\/1759-7714.13501","article-title":"Low-dose hilar and mediastinal stereotactic body radiation therapy for non-small cell lung cancer: Analysis of outcomes in patients receiving one or multiple courses of treatment","volume":"11","author":"Kowalchuk","year":"2020","journal-title":"Thorac. Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1001\/jama.2010.261","article-title":"Stereotactic body radiation therapy for inoperable early stage lung cancer","volume":"303","author":"Timmerman","year":"2010","journal-title":"JAMA"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1200\/JCO.18.00622","article-title":"Safety and efficacy of a five-fraction stereotactic body radiotherapy schedule for centrally located non-small-cell lung cancer: NRG oncology\/RTOG 0813 trial","volume":"37","author":"Bezjak","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1533033818803597","DOI":"10.1177\/1533033818803597","article-title":"Stereotactic Radiotherapy for Oligometastases in Lymph Nodes\u2014A Review","volume":"17","author":"Matsushita","year":"2018","journal-title":"Technol. Cancer Res Treat."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.cllc.2016.10.008","article-title":"Radiotherapy with curative intent in patients with early-stage, medically inoperable, non-small-cell lung cancer: A systematic review","volume":"18","author":"Falkson","year":"2017","journal-title":"Clin. Lung Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.ctrv.2015.04.002","article-title":"Available evidence on reirradiation with stereotactic ablative radiotherapy following high-dose previous thoracic radiotherapy for lung malignancies","volume":"41","author":"Filippi","year":"2015","journal-title":"Cancer Treat. Rev."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.euf.2017.07.006","article-title":"Exploring all avenues for radiotherapy in oligorecurrent prostate cancer disease limited to lymph nodes: A systematic review of the role of stereotactic body radiotherapy","volume":"3","author":"Ponti","year":"2017","journal-title":"Eur. Urol. Focus"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e623","DOI":"10.1016\/j.clgc.2017.01.004","article-title":"Salvage stereotactic body radiotherapy for isolated lymph node recurrent prostate cancer: Single institution series of 94 consecutive patients and 124 lymph nodes","volume":"15","author":"Fanetti","year":"2017","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.cllc.2011.03.007","article-title":"Phase I\/II trial of a COX-2 inhibitor with limited field radiation for intermediate prognosis patients who have locally advanced non-small-cell lung cancer: Radiation Therapy Oncology Group 0213","volume":"12","author":"Gore","year":"2011","journal-title":"Clin. Lung Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/S0360-3016(99)00130-3","article-title":"Effectiveness of accelerated radiotherapy for patients with inoperable non-small cell lung cancer (NSCLC) and borderline prognostic factors without distant metastasis: A retrospective review","volume":"44","author":"Nguyen","year":"1999","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/00130404-200607000-00006","article-title":"Local recurrence following initial resection of NSCLC: Salvage is possible with radiation therapy","volume":"12","author":"Kelsey","year":"2006","journal-title":"Cancer J."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"5883","DOI":"10.1200\/JCO.2005.55.405","article-title":"Combined chemoradiotherapy regimens of pacitaxel and carboplatin for locally advanced non-small cell lung cancer: A randomized phase II locally advanced multi-modality protocol","volume":"23","author":"Belani","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"5910","DOI":"10.1200\/JCO.2005.03.070","article-title":"Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d\u2019Oncologie Thoracique-Groupe Fran\u00e7ais de Pneumo-Canc\u00e9rologie NPC 95-01 Study","volume":"23","author":"Fournel","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"802949","DOI":"10.3389\/fonc.2021.802949","article-title":"Corrigendum: A Real-World, Multicenter, Observational Retrospective Study of Durvalumab After Concomitant or Sequential Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer","volume":"11","author":"Bruni","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"744956","DOI":"10.3389\/fonc.2021.744956","article-title":"A Real-World, Multicenter, Observational Retrospective Study of Durvalumab After Concomitant or Sequential Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer","volume":"11","author":"Bruni","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1056\/NEJMc1203770","article-title":"Central-airway necrosis after stereotactic body-radiation therapy","volume":"366","author":"Corradetti","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.ijrobp.2011.08.036","article-title":"Oligometastases treated with stereotactic body radiotherapy: Long-term follow-up of prospective study","volume":"83","author":"Milano","year":"2012","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1002\/cncr.20539","article-title":"Stereotactic hypofractionated high-dose irradiation for stage I nonsmall, cell lung carcinoma: Clinical outcomes in 245 subjects in a Japanese multiinstitutional study","volume":"101","author":"Onishi","year":"2004","journal-title":"Cancer"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.ijrobp.2010.12.039","article-title":"Stereotactic body radiotherapy for medically inoperable lung cancer: Prospective, single-center study of 108 consecutive patients","volume":"82","author":"Taremi","year":"2012","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"20160251","DOI":"10.1259\/bjr.20160251","article-title":"Stereotactic body radiotherapy for oligoprogressive cancer","volume":"89","author":"Cheung","year":"2016","journal-title":"Br. J. Radiol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1124\/pr.116.012682","article-title":"Targeting Immune Checkpoints in Hematologic Malignancies","volume":"68","author":"Alatrash","year":"2016","journal-title":"Pharmacol. Rev."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"152","DOI":"10.3389\/fonc.2015.00152","article-title":"Melanoma: From Incurable Beast to a Curable Bet. The success of Immunotherapy","volume":"5","author":"Ascierto","year":"2015","journal-title":"Front. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"De Felice, F., Marchetti, C., Palaia, I., Musio, D., Muzii, L., Tombolini, V., and Panici, P. (2015). Immunotherapy of Ovarian Cancer: The Role of Checkpoint Inhibitors. J. Immunol. Res., 91832.","DOI":"10.1155\/2015\/191832"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"5101","DOI":"10.2147\/OTT.S111209","article-title":"Immune Checkpoint Inhibitors: The New Frontier in Non-Small-Cell Lung Cancer Treatment","volume":"9","author":"Shahid","year":"2016","journal-title":"Onco Targets Ther."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1097\/MOU.0000000000000319","article-title":"Advances in Treatment of Metastatic Renal Cell Carcinoma","volume":"26","author":"Gong","year":"2016","journal-title":"Curr. Opin. Urol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"305","DOI":"10.21037\/atm.2016.08.29","article-title":"The Emerging Role of Immunotherapy in Colorectal Cancer","volume":"4","author":"Lynch","year":"2016","journal-title":"Ann. Transl. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s11912-018-0654-5","article-title":"Immunotherapy for Head and Neck Squamous Cell Carcinoma","volume":"20","author":"Moskovitz","year":"2018","journal-title":"Curr. Oncol. Rep."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s12094-018-02011-9","article-title":"The Role of Immunotherapy in Small Cell Lung Cancer","volume":"21","author":"Calles","year":"2019","journal-title":"Clin. Transl. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.ijrobp.2017.11.041","article-title":"Concurrent immune checkpoint inhibitors and stereotactic radiosurgery for brain metastases in non-small cell lung cancer, melanoma, and renal cell carcinoma","volume":"100","author":"Chen","year":"2018","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.3171\/2017.7.JNS171286","article-title":"Combination ipilimumab and radiosurgery for brain metastases: Tumor, edema, and adverse radiation effects","volume":"129","author":"Diao","year":"2018","journal-title":"J. Neurosurg."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s11060-018-2795-7","article-title":"The impact of timing of immunotherapy with cranial irradiation in melanoma patients with brain metastases: Intracranial progression, survival and toxicity","volume":"138","author":"Rahma","year":"2018","journal-title":"J. Neuro-Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ijrobp.2018.02.175","article-title":"Improved overall survival and locoregional disease control with concurrent PD-1 pathway inhibitors and stereotactic radiosurgery for lung cancer patients with brain metastases","volume":"101","author":"Schapira","year":"2018","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e1283461","DOI":"10.1080\/2162402X.2017.1283461","article-title":"Improved time to disease progression in the brain in patients with melanoma brain metastases treated with concurrent delivery of radiosurgery and ipilimumab","volume":"19","author":"Skrepnik","year":"2017","journal-title":"Oncoimmunology"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.wneu.2017.01.101","article-title":"SRS administration of immune checkpoint therapy for melanoma metastatic to the brain: Investigating efficacy and the effects of relative treatment timing on lesion response","volume":"100","author":"Yusuf","year":"2017","journal-title":"World Neurosurg."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.ijrobp.2015.01.004","article-title":"Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: Safety profile and efficacy of combined treatment","volume":"92","author":"Kiess","year":"2015","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s11060-018-2880-y","article-title":"Stereotactic radiosurgery and ipilimumab for patients with melanoma brain metastases: Clinical outcomes and toxicity","volume":"139","author":"Diao","year":"2018","journal-title":"J. Neurooncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1002\/cncr.30138","article-title":"Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery","volume":"122","author":"Qia","year":"2016","journal-title":"Cancer"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.3390\/curroncol29050244","article-title":"State of the Art in Combination Immuno\/Radiotherapy for Brain Metastases: Systematic Review and Meta-Analysis","volume":"29","author":"Najafi","year":"2022","journal-title":"Curr. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"746853","DOI":"10.3389\/fphar.2021.746853","article-title":"Biological Bases of Immune-Related Adverse Events and Potential Crosslinks With Immunogenic Effects of Radiation","volume":"2","author":"Bardoscia","year":"2021","journal-title":"Front. Pharmacol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/11\/2680\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:20:27Z","timestamp":1760138427000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/11\/2680"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,28]]},"references-count":70,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,6]]}},"alternative-id":["cancers14112680"],"URL":"https:\/\/doi.org\/10.3390\/cancers14112680","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,28]]}}}